Company intelligence / Profile preview
RemAb Therapeutics
Hospitalet de Llobregat / Barcelona area, Catalonia, Spainremabtx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
RemAb’s lead candidate RA-01/RA‑0127 targets Gram-negative bacterial infections and has completed preclinical regulatory studies with a first-in-human trial design validated by Spanish regulators. The technology offers immediate action without generating antimicrobial resistance and can be synthetically produced with an excellent safety profile. Several additional programs are at the preclinical stage targeting hematologic and immune system diseases.
- Therapeutic areas
- HematologyImmunologyInfectious Diseases
- Modalities
- polymeric glycoconjugatessynthetic polymeric conjugatesdrug conjugates
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on RemAb Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RemAb Therapeutics.